1.96
0.02 (0.92%)
| Penutupan Terdahulu | 1.94 |
| Buka | 1.99 |
| Jumlah Dagangan | 16,398 |
| Purata Dagangan (3B) | 153,159 |
| Modal Pasaran | 50,754,400 |
| Harga / Jualan (P/S) | 1.95 |
| Harga / Buku (P/B) | 0.870 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Aug 2024 - 13 Aug 2024 |
| Margin Keuntungan | -85.75% |
| Margin Operasi (TTM) | -748.92% |
| EPS Cair (TTM) | -0.540 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -69.70% |
| Nisbah Semasa (MRQ) | 10.68 |
| Aliran Tunai Operasi (OCF TTM) | -11.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.70 M |
| Pulangan Atas Aset (ROA TTM) | -21.35% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Ocuphire Pharma, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.0 |
| Purata | 0.17 |
|
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 6.11% |
| % Dimiliki oleh Institusi | 8.70% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |